AngioWaveNet vs A View LCS
AI Verdict
Choose AngioWaveNet if…
Choose AngioWaveNet if your primary need is to enhance the clarity and visibility of blood vessels during fluoroscopic angiograms in a cardiac catheterization laboratory. This tool is ideal for interventional cardiologists, radiologists, or vascular surgeons seeking to improve real-time procedural guidance and diagnostic accuracy by leveraging AI-powered post-processing that integrates seamlessly with existing cath lab workflows.
View AngioWaveNet →Choose A View LCS if…
Choose A View LCS if your institution requires a comprehensive AI platform for analyzing thoracic CT scans, particularly for robust lung cancer screening programs, emphysema quantification, and coronary artery calcification assessment. This solution is best suited for radiologists and pulmonologists looking to automate and standardize the detection, measurement, and reporting of multiple thoracic pathologies from a single low-dose CT scan.
View A View LCS →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | AngioWaveNet | A View LCS |
|---|---|---|
| Pricing | Pricing options include annual software licensing or subscription-based access, tailored to cath lab volume and hospital needs. custom packages are available. | Unknown |
| Deployment | Cloud-based or on-premise/servers | Cloud-based, Hybrid solution, Locally on dedicated hardware, Locally virtualized (virtual machine, Docker). It can also be integrated into standard reading environments (PACS), RIS (Radiological Information System), or used as a standalone third-party application or web-based application. |
| FDA Status | Cleared AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
AngioWaveNetAngioWaveNet emphasizes seamless integration into existing Cath lab workflows, vendor-agnostic compatibility, and minimal training, allowing for immediate use and side-by-side review without procedural delays. This focus on direct workflow integration and ease of adoption gives it an edge in usability.
Clinical Value
A View LCSAVIEW LCS offers a broader and more comprehensive clinical value by providing integrated detection and fully automatic analysis for three major thoracic diseases (lung cancer, COPD, and cardiovascular disease) from a single low-dose CT scan. This multi-faceted diagnostic capability, including automated scoring and reporting, significantly enhances efficiency and diagnostic scope.
Pricing & Value
AngioWaveNetAngioWaveNet provides more transparency regarding its pricing structure by outlining options like annual software licensing, subscription-based access, and custom packages tailored to hospital needs. While specific figures are not provided, this structured approach offers a clearer understanding of potential cost models compared to AVIEW LCS's 'contact for quote.'
Enterprise Readiness
A View LCSAVIEW LCS demonstrates superior enterprise readiness due to its wider array of deployment options, including cloud, hybrid, local hardware, and virtualized environments, offering greater flexibility for diverse IT infrastructures. Additionally, the explicit mention of having a Business Associate Agreement (BAA) further solidifies its commitment to data security and compliance for enterprise clients.
Innovation
A View LCSAVIEW LCS showcases greater innovation by integrating AI for comprehensive multi-disease analysis (lung cancer, COPD, and cardiovascular disease) from a single low-dose CT scan, including automated scoring and reporting. This holistic approach to diagnostic imaging, encompassing multiple critical pathologies, represents a significant advancement in efficiency and early detection.
Support & Docs
AngioWaveNetAngioWaveNet explicitly details its comprehensive support offerings, including full onboarding, installation assistance, staff training, and access to ongoing updates and clinical resources. It also mentions providing software documentation as per FDA guidance. While AVIEW LCS's partners mention support documentation, AngioWaveNet's description provides a more concrete and extensive outline of its support ecosystem.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | AngioWaveNet | A View LCS |
|---|---|---|
| Name | AngioWaveNet | A View LCS |
| Company | Angiowave Imaging | Coreline Soft Co. |
| Description | AngioWaveNet is FDA-cleared AI software that enhances fluoroscopic angiograms for improved vessel visualization in cardiac catheterization laboratories, integrating with existing Cath lab workflows. | AVIEW LCS by Coreline Soft is an FDA-cleared AI-powered medical imaging platform for comprehensive thoracic CT analysis, specializing in lung cancer screening, emphysema quantification, and coronary artery calcification detection from a single low-dose CT scan. |
| Primary Specialties | Cardiology, Interventional Radiology, Vascular Surgery | Cardiology, Pulmonology, Radiology |
| Key Features (Examples) | AI-powered Spatiotemporal Enhancement Processing (STEPu2122), Improved vessel visualization in fluoroscopic angiograms, Integrates with existing Cath lab workflows | Automated lung nodule detection and classification, Nodule volume quantification and measurement (3D), Lung-RADS scoring and reporting |
Videos
Demos, reviews, and walkthroughs featuring AngioWaveNet and A View LCS.